ITG-HM451-100μg / 询价
ITG-HM451-500μg / 询价
ITG-HM451-500μgx2 / 询价
- 客服电话
- 技术支持
Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein
Recombinant Human Integrin alpha 5 beta 1 (ITGA5&ITGB1) Heterodimer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Phe42-Tyr995(ITGA5) acidic tail and Gln21-Asp728(ITGB1) basic tail [Accession | P08648(ITGA5)&P05556-1(ITGB1)].
The protein has a predicted MW of 111.8 kDa (ITGA5) & 83.2 kDa (ITGB1). Due to glycosylation, the protein migrates to 100-140 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 24 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human ITGA5&ITGB1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human ITGA5&ITGB1 is greater than 95% as determined by SEC-HPLC.
Immobilized Human ITGA5&ITGB1, His Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Anti-ITGA5&ITGB1 Antibody, hFc Tag with the EC50 of 16.6ng/ml determined by ELISA (QC Test).
Integrin alpha 5/ beta 1, also known as VLA-5, is a widely expressed non-covalent heterodimer of a 160 kDa alpha 5 and a 130 kDa beta 1 Integrin subunit.Alpha 5/ beta 1 is up‑regulated on tumor vasculature and promotes angiogenesis.
Integrin alpha 5 beta 1; VLA-5; ITGA5&ITGB1;Integrin alpha 5 β 1; α5β1
(1)Zhang Z , Vuori K , Reed J C , et al. The alpha5beta1 Integrin Supports Survival of Cells on Fibronectin and Up-Regulates Bcl2 Expression[J]. Proceedings of the National Academy of Sciences, 1995, 92(13):6161-6165.
(2)Ramakrishnan V , Bhaskar V , Law D A , et al. Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent[J]. Journal of Experimental Therapeutics and Oncology, 2006, 5(4):273-286.
